Article
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure - Nature Immunology
Rating:
0.0
Views:
90
Likes:
1
Library:
1
Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve durable responses. G-protein-coupled receptors (GPCRs) are the most intensively studied drug targets but are underexplored in immuno-oncology.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value